Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 5:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: P2Y12 Clear all
Completed No phase listed Observational

Influence of the Proton Pump Inhibitor Omeprazole on the Anti-Platelet of P2Y12 Antagonists in Subjects With Coronary and Peripheral Artery Disease

NCT01018940
View directory record Official record
Conditions
Coronary Artery Disease, Peripheral Artery Disease
Interventions
Not listed
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Sep 13, 2026, 5:06 PM EDT
Completed Phase 4 Interventional Results available

Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI

NCT04483583
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 60mg, Clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 13, 2026, 5:06 PM EDT
Completed Phase 4 Interventional Results available

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

NCT02545933
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Prasugrel, Vorapaxar, Aspirin, Ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 13, 2026, 5:06 PM EDT
Terminated Phase 2 Interventional Results available

Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)

NCT00910299
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Clearwater, Florida • Jacksonville, Florida • Rome, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Sep 13, 2026, 5:06 PM EDT
Completed Phase 4 Interventional Results available

Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

NCT04006288
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel, Prasugrel, ticagrelor, aspirin, rivaroxaban
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 13, 2026, 5:06 PM EDT
Completed Phase 2 Interventional

A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI

NCT00751231
View directory record Official record
Conditions
Percutaneous Coronary Intervention
Interventions
clopidogrel, PRT060128
Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
La Jolla, California • Torrance, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 13, 2026, 5:06 PM EDT
Recruiting Phase 4 Interventional

The Switching Antiplatelet-9 (SWAP-9) Study

NCT06588595
View directory record Official record
Conditions
Coronary Arterial Disease (CAD)
Interventions
Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel, Aspirin plus clopidogrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 13, 2026, 5:06 PM EDT
Terminated Phase 4 Interventional

Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty

NCT00289601
View directory record Official record
Conditions
Angioplasty
Interventions
eptifibatide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2007 · Synced Sep 13, 2026, 5:06 PM EDT
Not listed Phase 4 Interventional

Implementing Precision Medicine Approaches to Guide Anti-platelet Selection

NCT04090281
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS), STEMI - ST Elevation Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation MI, Unstable Angina (UA)
Interventions
CYP2C19 genotyping
Genetic
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 13, 2026, 5:06 PM EDT
Completed Not applicable Interventional Results available

XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.

NCT03218787
View directory record Official record
Conditions
Coronary Artery Lesions
Interventions
XIENCE, DAPT
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,047 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
101
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 88 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 13, 2026, 5:06 PM EDT
Terminated Phase 3 Interventional Results available

A Clinical Trial to Demonstrate the Efficacy of Cangrelor

NCT00305162
View directory record Official record
Conditions
Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
Interventions
Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor), Placebo bolus & placebo infusion, Placebo capsules - end of infusion, Placebo capsules - as soon as possible after randomization
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
8,882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Sep 13, 2026, 5:06 PM EDT
Recruiting Not applicable Interventional

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

NCT07613840
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Salem, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 13, 2026, 5:06 PM EDT
Completed Phase 4 Interventional Results available

Ticagrelor Therapy for RefrACTORy Migraine Study

NCT02518464
View directory record Official record
Conditions
Migraine, Headache, Migraine Headache
Interventions
Ticagrelor 90 mg twice per day
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 13, 2026, 5:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants

NCT07133191
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Selatogrel, Matching placebo
Combination Product
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
20 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 13, 2026, 5:06 PM EDT
Terminated Phase 4 Interventional

Ticagrelor and Peripheral Arterial Disease

NCT02407314
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Percutaneous Peripheral Intervention, Optical Coherence Tomography, Ankle Brachial Index, Six minute walk distance, Aspirin, Aspirin + Ticagrelor
Procedure · Device · Other + 1 more
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Sep 13, 2026, 5:06 PM EDT
Completed Not applicable Interventional

Evaluating Pharmacogenomic Variants for Cardiology Therapeutics

NCT04702113
View directory record Official record
Conditions
Thrombosis, Stent Thrombosis, Bleeding, Myocardial Infarction, Ischemic Stroke
Interventions
Cipherome Lighthouse Pilot
Diagnostic Test
Lead sponsor
Cipherome, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Edinburg, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 13, 2026, 5:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

NCT03430661
View directory record Official record
Conditions
Healthy
Interventions
ACT-246475, Clopidogrel, Prasugrel, Placebo, Ticagrelor
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 13, 2026, 5:06 PM EDT
Recruiting Phase 3 Interventional

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

NCT04045665
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
51
States / cities
Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 13, 2026, 5:06 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

NCT05681702
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
aspirin plus clopidogrel, prasugrel or ticagrelor
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 13, 2026, 5:06 PM EDT
Terminated Phase 2 Interventional Results available

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

NCT02227368
View directory record Official record
Conditions
Peripheral Artery Disease (PAD)
Interventions
Ticagrelor, Comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Daytona Beach, Florida • Jacksonville, Florida • Ocala, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Sep 13, 2026, 5:06 PM EDT
Completed Not applicable Interventional Results available

XIENCE 28 USA Study

NCT03815175
View directory record Official record
Conditions
Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases, Thrombocytopenia, Coagulation Disorder, Anemia, Renal Insufficiency, Coronary Artery Disease
Interventions
XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
54
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 13, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease

NCT03384966
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Selatogrel, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
7
States / cities
Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 13, 2026, 5:06 PM EDT
Completed No phase listed Observational

Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization

NCT03889574
View directory record Official record
Conditions
Cardiac Disease
Interventions
Not listed
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Sep 13, 2026, 5:06 PM EDT
Completed Phase 4 Interventional Results available

Chewed Versus Integral Pill of Ticagrelor

NCT03708588
View directory record Official record
Conditions
Percutaneous Coronary Intervention
Interventions
Ticagrelor
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 89 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Sep 13, 2026, 5:06 PM EDT